Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population

Abstract

Purpose

Racial differences in the incidence of prostate cancer on initial biopsy are well established, but the predictive value of African American race on the probability of prostate cancer detection on repeat biopsy is unknown.

Materials and methods

At a single institution between January 2007 and June 2014, we reviewed 277 men who first underwent a negative transrectal ultrasound guided needle biopsy of the prostate, and who then subsequently underwent a second biopsy. Detection rates were compared via Chi-square analysis. Race, age, PSA, presence of high-grade prostatic intraepithelial neoplasia, presence of atypical small acinar proliferation, prostate volume, PSA velocity and PSA density were compared via a multivariate logistic regression analysis.

Results

496 AA men and 352 Caucasian men underwent initial biopsy, and AA men had a 49 % cancer detection rate, compared to 34 % in Caucasians (p < 0.0001). AA men also had a greater incidence of Gleason 7 cancers (p = 0.00018) and a smaller mean TRUS volume (p = 0.006) compared to Caucasians. On repeat biopsy, AA men no longer had a higher cancer detection rate (p = 0.227), nor difference in Gleason 7 detection or TRUS volume (p = 0.0992). On initial biopsy, AA race and increasing PSA were both associated with an increased likelihood for cancer detection (p < 0.001 for both). After an initial negative biopsy, AA race no longer predicted for future malignancy detection (p = 0.57), nor did PSA (p = 0.36).

Conclusions

In a cohort of men with high pre-test probability of prostate cancer and an initial negative biopsy, African American race in a veteran population fails to predict the detection of future prostate cancer.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Siegel R, Ma J, Zou Z et al (2014) Cancer statistics. CA Cancer J Clin 64:9–29

  2. 2.

    Barry MJ (2009) Screening for prostate cancer–the controversy that refuses to die. N Engl J Med 360(13):1351–1354. doi:10.1056/NEJMe0901166. (Epub 2009 Mar 18)

  3. 3.

    Moyer VA (2012) United States preventive services task force. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157(2):120–134. doi:10.7326/0003-4819-157-2-201207170-00459

  4. 4.

    Carter HB et al (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419–426. doi:10.1016/j.juro.2013.04.119

  5. 5.

    NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2015. National Comprehensive cancer Network, Inc (2015)

  6. 6.

    Gaines Alexis R et al (2014) The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort. Cancer Causes Control 25:1029–1035

  7. 7.

    Bigler SA et al (2011) A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011, Article ID 239460

  8. 8.

    Gann Peter H et al (2010) Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 28(10):1714–1720

  9. 9.

    Yanke BV, Salzhauer EW, Colon I (2006) Is race a positive predictor of cancer on repeat prostate biopsy? J Urol 176:1114–1117

  10. 10.

    Carver BS, Bozeman CB, Simoneaux WJ et al (2004) Race is not a predictor of prostate cancer detection on repeat prostate biopsy. J Urol 172:1853–1855

  11. 11.

    Connolly D, Black A, Murray LJ et al (2007) Methods of calculating prostate-specific antigen velocity. Eur Urol 52:1044–1051

  12. 12.

    Welch HG, Fisher ES, Gottlieb DJ et al (2007) Detection of prostate cancer via biopsy in the medicare-SEER population during the PSA era. J Natl Cancer Inst 99:1395

  13. 13.

    Djavan B, Ravery V, Zlotta A et al (2001) Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166(5):1679

  14. 14.

    Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G et al (2009) Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 55(3):600

  15. 15.

    Pinsky PF, Parnes HL, Andriole G (2014) Mortality and complications after prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening (PLCO) trial. BJU Int 113(2):254

  16. 16.

    Loeb S, Carter HB, Berndt SI et al (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5):1830–1834. doi:10.1016/j.juro.2011.06.057. (Epub 2011 Sep 23)

  17. 17.

    Oba A, Nakaya N, Hasumi M et al (2014) Psychosocial longitudinal study profile and distress of couples in relation to the conduct of prostate biopsy. Jpn J Clin Oncol 44(5):463–471. (Epub 2014 Mar 18)

  18. 18.

    Welch HG, Fisher ES, Gottlieb DJ et al (2007) Detection of prostate cancer via biopsy in the medicare-SEER population during the PSA era. J Natl Cancer Inst 99:1395

  19. 19.

    Hoffman RM, Gilliland FD, Eley JW et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 93(5):388

  20. 20.

    Gann Peter H et al (2010) Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Onc 28(10):1714–1720

  21. 21.

    Ploussard G et al (2013) Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial. Br J Urol Int 111:988–996

  22. 22.

    Lopez-Corona et al (2003) A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 170:1184–1188

  23. 23.

    Kitagawa Y et al (2015) Simple risk stratification to detect prostate cancer with high gleason score in repeat biopsies in a population screening follow-up study. Anticancer Res 35:5031–5036

  24. 24.

    Abouassaly R, Tan N, Moussa A et al (2008) Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol 180(3):911

  25. 25.

    Amin MM, Jeyaganth S, Fahmy N et al (2007) Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation. Can Urol Assoc J 1(3):245

  26. 26.

    Ploussard G, Plennevaux G, Allory Y et al (2009) High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance. World J Urol 27(5):587

  27. 27.

    De Nunzio C, Trucchi A, Miano R et al (2009) The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 181(3):1069

  28. 28.

    Gallo F, Chiono L, Gastaldi E et al (2008) Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies. Urology 72(3):628

  29. 29.

    Gittelman MC, Hertzman B, Bailen J et al (2013) PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 190(1):64–69. doi:10.1016/j.juro.2013.02.018 (Epub 2013 Feb 14)

  30. 30.

    Robertson NL, Emberton M, Moore CM et al (2013) MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol 10(10):589–597 (Epub 2013 Sep 24 Review)

  31. 31.

    Kuru TH, Roethke MC, Seidenader J et al (2013) Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 190(4):1380–1386. doi:10.1016/j.juro.2013.04.043 (Epub 2013 Apr 19)

  32. 32.

    Vourganti S, Rastinehad A, Yerram NK et al (2012) Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 188(6):2152–2157. doi:10.1016/j.juro.2012.08.025 (Epub 2012 Oct 18)

  33. 33.

    Roethke M, Anastasiadis AG, Lichy M et al (2012) MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 30(2):213–218. doi:10.1007/s00345-011-0675-2 (Epub 2011 Apr 22)

  34. 34.

    Taira AV, Merrick GS, Galbreath RW et al (2010) Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 13(1):71–77. doi:10.1038/pcan.2009.42 (Epub 2009 Sep 29)

  35. 35.

    Zaytoun OM, Moussa AS, Gao T et al (2011) Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 186(3):850–854. doi:10.1016/j.juro.2011.04.069 (Epub 2011 Jul 23)

Download references

Author contributions

William Sterling has full access to all of the data and takes responsibility for the integrity and accuracy of the data analysis in this study. Study concept and design: Sterling, Weiss, Schreiber; Drafting of manuscript: Sterling, Weiner, Schreiber, Weiss; Critical revision of manuscript: Weiner, Schreiber, Weiss, Sterling; Statistical analysis: Schreiber, Sterling; Interpretation of data: Sterling, Weiner, Schreiber, Weiss; Administrative, technical support: Mehta, Weiss, Schreiber; Study supervision: Weiss, Schreiber.

Author information

Correspondence to William A. Sterling.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sterling, W.A., Weiner, J., Schreiber, D. et al. The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population. Int Urol Nephrol 48, 2015–2021 (2016). https://doi.org/10.1007/s11255-016-1407-8

Download citation

Keywords

  • Prostate cancer
  • Repeat biopsy
  • African American
  • Race